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Abstract Tuberculosis (TB) is one of the world’s
leading causes of death due to infection and efforts to
control TB would be substantially aided by the
availability of an improved TB vaccine. There are
currently nine new TB vaccines in clinical develop-
ment, and the first efficacy trials are due to commence
in 2009. There are many complex ethical issues which
arise at all stages of TB vaccine development, from
the need to conduct trials in developing countries to
informed consent and the process of ethical review.
While it is important that these issues are discussed, it
may also be timely to consider the challenges which
may arise if a vaccine in clinical development proves
to be highly effective. We examine a number of
scenarios where decisions on the deployment of a
new TB vaccine may impact on the rights and liberty
of the individual.
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Introduction
The World Health Organization (WHO) declared
tuberculosis (TB) a global health emergency in 1993
with good reason; sixteen years later the scale of the
problem remains an urgent global challenge. With
more than 9 million new cases and almost two million
deaths each year, TB is one of the world’s leading
infectious causes of illness and death (WHO 2007).
Effective methods of diagnosing and treating TB already
exist and yet, due to (population increases and) increases
in HIV-associated TB in Africa and the emergence
of multidrug-resistant strains of Mycobacterium
tuberculosis (M. tb), the global incidence of TB is
increasing (Corbett et al. 2003). Despite its global
impact there has been a lack of discussion of the ethical
issues related to TB (Selgelid et al. 2008a, 2008b).
These issues include individual obligations to avoid
infecting others, coercive social distancing measures
to prevent the spread of infection, breaching confi-
dentiality through notification of contacts of TB
patients and health workers’ duty to treat contagious
patients (Selgelid et al. 2008b). There are both moral
and self-interested reasons for wealthy nations to do
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more to help reduce the burden of TB in developing
countries; and ethicists should evaluate whether it
would be more effective to focus spending on
research and development, or on improving healthcare
infrastructure. Ethical policy for infectious disease
control should aim to strike a balance between
protecting rights/liberties of infected individuals and
promoting the greater good of society in the way of
public health (Selgelid 2005). Many of the ethical
issues related to infectious disease, such as coercive
social distancing and breaching of confidentiality
through notification of contacts, could be avoided if
diseases were eradicated or infection prevented. The
most effective and cost-effective tool for disease
prevention is vaccination. The only existing licensed
vaccine against TB is a substrain of M. bovis, Bacille
Calmette Guérin, or BCG. This vaccine, developed
around the turn of the last century and first adminis-
tered in 1921, is given to a large proportion of
newborn infants throughout the world in the hope that
it will protect them against TB. However, the
protection BCG confers against TB is both incomplete
and variable (Colditz et al. 1994).
We submit that a new TB vaccine, or vaccine
regimen, which would ideally be effective in all
populations and all age groups, against all stages of
TB infection and disease (for example latent, pulmo-
nary and extra-pulmonary TB) is the only affordable
and realistic long-term solution to the global TB
epidemic.
There are many important ethical issues to be
considered in the development of a new vaccine for
an epidemic disease such as TB. As with all medical
research on humans, TB vaccine trials must be
conducted according to the principals of the Declara-
tion of Helsinki, most recently updated in 2008
(WMA 2008), and the Belmont Report (U. S.
Department of Health, Education and Welfare 1979).
The latter establishes the principles of 1) Respect for
persons 2) Beneficence and 3) Justice. Most previ-
ously published work on TB vaccines has focused
primarily on the issue of informed consent (Ibanga et
al. 2006; Minnies et al. 2008; Snider 2000). Selgelid
et al. have previously described the ethical issues
associated with TB disease (Selgelid et al. 2008a,
2008b). Using these documents as guides, we
consider the ethical challenges which face TB vaccine
development and deployment; and we highlight some
of the ethical issues that warrant further consideration.
Challenges to Decision Making in Vaccine
Development
One of the first efficacy trials of a new generation
vaccine designed to boost an antigen specific T cell
response was the STEP trial, which assessed the
efficacy of an adenovirus type 5 (Ad5)-based vaccine
designed to prevent HIV infection. In the STEP trial,
vaccination of men with pre-existing Ad5 immunity
unexpectedly resulted in a higher incidence of HIV-1
infection, when compared to placebo-vaccinated men
(Buchbinder et al. 2008). This led to an extensive and
detailed review of the preclinical efficacy and preclin-
ical and clinical immunogenicity data obtained with
the Ad5-based vaccine, to determine if the outcome of
the STEP trial could have been predicted (McElrath
et al. 2008). The vaccine was protective in most animal
models and immunogenic in both animals and humans.
This highlights two critical problems with the devel-
opment of vaccines for cell mediated immunity: 1) a
lack of validated preclinical models which predict the
efficacy of a vaccine in humans; and 2) an incomplete
understanding of the components of a protective
immune response. It is important that we learn from
the experiences of the STEP trial in order that we
protect patient-subjects, use what limited resources we
have in the most effective manner and develop and
deploy a more effective TB vaccine.
Progression from Pre-clinical to Clinical Testing
One ethical issue raised by progression from pre-
clinical to clinical vaccine testing is distributive
justice. There are limited resources for conducting
TB vaccine trials, so some fair means of allocating
scarce resources must be determined. In addition to
safety, the two primary methods used for selecting a
TB vaccine candidate are discussed below.
Efficacy Testing in Animal Models
The first experiments which demonstrated that a sub-
unit TB vaccine could protect mice against challenge
with virulent M. tb were published in 1996 (Huygen
et al. 1996; Tascon et al. 1996). There was optimism
at the time that an improved TB vaccine would soon
be available for human use. Since that time, there
have been hundreds of reports of experimental
vaccines demonstrating protection against challenge
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with M. tb in mice; yet, to date, only nine of these
vaccines have progressed to clinical trials. The most
commonly used murine model can be highly variable
and the same vaccine candidate can demonstrate
100% protective efficacy to no protective efficacy
depending on factors such as the species of animal
used, the route of vaccination, the interval between
vaccination and challenge, the route and dose of
challenge and the interval between challenge and
termination (Orme 2005). The limitations of the
murine model are well illustrated by the consistent
protective effect of BCG vaccination in mice. If BCG
were as consistently good in humans, the need for a
new TB vaccine would be much less urgent.
Limitations of the murine model have led to the
experimental use of other animal species including
guinea pigs, rabbits, non-human primates and cattle.
All preclinical animal experiments are expensive, and
time consuming (usually running for more than
6 months); and they require highly specialized
Category 3 biocontainment facilities, which are not
widely available.
Do we understand enough about the strengths and
limitations of our models to use animal data as a basis
for the selection of vaccine candidates? Is it ethical to
accept or reject a candidate on the basis of preclinical
animal efficacy data? It is unlikely that any candidate
vaccines would progress through preclinical testing to
early stage clinical testing without any evidence of
efficacy. Collaborative efforts such as those funded by
the NIH and European Commission Framework 6
TBVAC cluster have tested many TB vaccine candi-
dates in multiple animal species (Baldwin et al. 1998;
Williams et al. 2005). In the TBVAC project funding
was provided for head-to-head testing of several new
TB vaccine candidates from various sponsors. Such
comparative experiments will remain necessary if we
are to maximize the possibility of selecting the safest
and most protective vaccine candidates for further
development.
Measurement of Immunogenicity
There is no proven immunological correlate of
protection with which one can select vaccines to
progress from early, small scale Phase I/IIa clinical
trials to late, larger scale Phase IIb/III efficacy trials.
The identification of an immunological correlate of
protection or “biomarker” would greatly facilitate the
development of a vaccine for TB, as such a biomarker
could be used to identify protective vaccines early in
clinical development. Currently, interferon-gamma
(IFN-γ) is used as a biomarker for TB vaccine
selection, despite the fact that IFN-γ alone is
insufficient for the prevention of TB disease.
Is it reasonable to select vaccine candidates on the
basis of an ability to induce antigen-specific IFN-γ,
when we know that this immunological measurement
alone is not sufficient for protection? Although we do
not yet have a better biomarker than IFN-γ, efforts
should be made to harmonise the immunological
assays in use for the measurement of IFN-γ in
clinical trials which are currently being conducted
in various countries worldwide (Hanekom et al.
2008). Finally, it is also important that we store
samples from larger efficacy trials to enable the
identification of biomarkers that could be used to
select promising vaccines and aid in the just distri-
bution of the limited resources available for TB
vaccine development.
Progression from Phase I Safety Trials to Phase III
Efficacy Trials
Ethical principles considered here include beneficence
and distributive justice.
Non-inferiority, Clinical Superiority and Placebos
A double blind, randomized, placebo controlled trial
is considered the optimum design for a phase III
efficacy trial. For a disease where no current vaccine
is available (such as for HIV or malaria) the ethics of
trial design is focused on appropriate sample size and
selection of placebo. The rabies vaccine is considered
a good placebo for malaria as this will offer some
benefit to those participants not receiving the malaria
vaccine. For a new TB vaccine the scenario is
different due to the currently available TB vaccine,
BCG. BCG is one of the most widely administered
vaccines in the world and despite varying efficacy
does provide some protection against childhood forms
of TB. To date it has been the view of researchers,
ethics committees and regulatory agencies that in a
country where TB is endemic it would be unethical to
withhold the BCG vaccine in a randomized control
trial of a new TB vaccine. This view has driven the
development of vaccines designed to work in combi-
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nation with BCG and slowed the development of
vaccines designed to replace BCG. For a vaccine
designed to enhance previous BCG vaccination, a
randomized placebo controlled trial of the boosting
vaccine is possible without withdrawing BCG vaccina-
tion. To facilitate the development of vaccines designed
to replace BCG the European Commission TBVAC
consortiumwith co-sponsorship of the Aeras Global TB
Vaccine Foundation and the WHO have formed a
consensus document of the proposed entry criteria for
replacement vaccines (Kamath et al. 2005). The
availability of the BCG vaccine also raises the question
of whether a new TB vaccine should demonstrate non-
inferiority or clinical superiority to BCG. A non-
inferiority trial aims to demonstrate that the new
vaccine is not worse than the comparator by more
than a pre-specified, small amount. There has been
much debate about the ethics of performing non-
inferiority trials relating to the principle of beneficence
where it is the duty of healthcare workers to provide a
benefit to the patient. While some argue that the
introduction of a non-inferior drug would increase
availability and affordability (Soliman 2008) the
alternative view is that non-inferiority trials are
unethical since a product tested in this way is not
(afterwards) proven to offer benefit when compared to
the existing treatment and may indeed be less safe and
less effective than the existing treatment (Garattini and
Bertele 2007). The first clinical efficacy trials of two
new TB vaccines are due to commence in 2009 and
both these trials are designed to show clinical
superiority when compared to BCG.
Lack of Global Capacity for Vaccine Efficacy
Evaluation
A major challenge facing TB vaccine developers is
the limited availability of suitable field sites where TB
vaccine efficacy trials can be conducted, together with
a relative lack of funding for such sites. TB trials are
likely to be very costly, because of their size and
because of the length of follow-up required, which is
directly linked to the lack of an acceptable validated
immunological surrogate endpoint. Clinical efficacy
endpoints take time to develop, so follow up in a TB
efficacy trial is unlikely to be less than a year and
probably two or more years. The result is that a
restricted number of vaccine candidates can progress
to Phase IIb and III efficacy trials, and efforts are
being made to address this bottleneck by Aeras and
by the European and Developing Countries Clinical
Trials Partnership (EDCTP). Until more trial sites
become available ethicists should examine how
clinical trial sites are used to ensure that the principles
of distributive justice are adhered to as vaccine
candidates are selected for efficacy testing.
A new, more protective TB vaccine could potentially
be used anywhere where BCG is currently used,
including in many lower burden countries and even in
areas where BCG is not currently used. The available
literature on BCG shows that its efficacy in preventing
TB disease varies widely with factors such as geo-
graphical latitude; for example BCG has been demon-
strated to be efficacious in Britain and North America,
but not so in India and Africa (Colditz et al. 1994).
Given this variability, it is possible that a new TB
vaccine which is of benefit in one population may not
be of benefit in different regions of the world. How
many countries or regions of the world should be
included in efficacy evaluations and how do you
determine if such multiple evaluations are an effective
use of scarce resources? Given the high burden of TB
disease in sub-Saharan Africa, we feel that any new
TB vaccine must first be evaluated there. It would be
desirable also to show efficacy within the Indian
subcontinent and in South-East Asia, in part because
of the appreciable burden of disease in these two areas
(both in terms of TB incidence rates, but more
especially in terms of absolute numbers of cases of
TB). A non-inferiority trial may be an ethical trial
design when comparing the efficacy of a new TB
vaccine between different countries.
Exclusion of HIV Infected Individuals from Trials
All early trials of new TB vaccines have thus far
excluded HIV infected individuals. This group is
considered to be at higher risk for adverse events than
the HIV negative population and vaccines are only
evaluated in HIV positives once safety has been
demonstrated in HIV negative people. Whilst this
cautious approach is logical, there is a need to
evaluate new TB vaccines in the HIV-infected, since
they are arguably the population most in need of a
new TB vaccine, with annual TB incidence rates of
between 5–10% (and potentially higher) depending
on the degree of immune suppression and access to
antiretroviral therapy. This higher incidence of TB
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means that efficacy can be evaluated using smaller
numbers of participants, once safety (in others) has
been confirmed. TB efficacy trials for HIV positive
populations are currently in the planning stages and
study participants will receive the usual standard of
care provided by their National Control Programme.
For this reason the first trials will be conducted in
countries that have a National Control Programme
which includes the availability of anti-retroviral
drugs. To ensure safety we will work in close contact
with the healthcare workers who usually provide care
and HIV viral loads and CD4 counts of study
participants will be closely monitored.
Involvement of Pharmaceutical Companies
Ideally, we need the involvement of pharmaceutical
companies in the development of drugs and vaccines
for poverty related diseases, in order to work with the
Global Alliance for Vaccines and Immunization
(GAVI), UNICEF and the Global Fund to ensure
these products reach the markets for which they are
intended in a timely fashion. Historically, these
companies have been reluctant to invest time and
resources into developing such products, possibly
because—at least in part—of perceptions that any
financial return on such an investment would be
improbable. More recently, several innovative
schemes and mechanisms have been established, in
order to encourage pharmaceutical involvement in
this field. Firstly, under the European Medicines
Agency (EMEA) and the U.S. Food and Drug
Administration (FDA) is the Orphan Drug Scheme
(http://www.emea.europa.eu/htms/human/orphans/
intro.htm and http://www.fda.gov/orphan/). If a mar-
ket is considered small enough (e.g. for a rare disease)
or if the financial return on a product is likely to be
very low (e.g. for prophylactic vaccination against a
poverty related disease), then the developers can
apply to the regulatory authorities (the FDA and/or
the EMEA) to have their product designated an
Orphan Drug. Such a designation provides benefit to
the developer, including free regulatory advice esti-
mated by the EMEA to be worth €6,000,000. Another
benefit of being accorded Orphan Drug status is the
award of 7-year and 10-year market exclusivity by the
FDA and EMEA respectively. There is an ethical
concern that such exclusivity could lead to excessive
pricing of drugs for rare diseases (Samson 2008). As
95% of the market for a poverty related disease, such
as TB, will be developing-country based the pricing
of the vaccine will be restricted, and therefore even
10-years market exclusivity in Europe is not expected
to provide a sufficient return on investment. The
exclusivity period may also be broken if the holder of
the original orphan vaccine gives consent; is unable to
supply sufficient quantities; or if the second vaccine is
proved clinically superior.
Secondly, under the GAVI Alliance, the Advance
Purchase/Market Commitment Scheme (http://www.
vaccineamc.org/) involves promises by governments
and agencies to procure stated quantities of new drugs
and vaccines (meeting pre-specified criteria) at
a predetermined price. Such commitments provide
pharmaceutical companies with reassurance concern-
ing a financial return on their investment and thus
provide an incentive to conduct more research and
development of drugs and vaccines for neglected
diseases.
Thirdly, the FDA recently launched the Priority
Review Voucher Scheme (http://www.fda.gov/cber/
gdlns/tropicaldisease.htm). In return for filing an
application on a product designed for a listed disease
of poverty, a company receives a voucher which
allows for “priority regulatory review” of one other
product that the company is developing. These
vouchers may be traded and sold—and they have
high expected value when used to expedite approval
of potential new “blockbuster” drugs.
Such schemes make it more likely that pharma-
ceutical companies will invest in the development of
a vaccine for a disease such as TB. Whilst they
offer reasonable incentives for pharmaceutical com-
panies, mechanisms should be established to ensure
that, once licensed, such a vaccine is made available
at or below (subsidized) cost-price to the govern-
ments of high TB burden countries, where it is most
needed.
A related question is whether the incentives
provided by the Orphan Drug Scheme are sufficient,
and whether there is scope for this to increase. Just as
many governments offer motorists tax breaks for
using environmentally friendly cars, they might offer
pharmaceutical companies tax breaks for investing in
diseases such as TB, HIV and malaria. We posit that
such additional incentives would increase the number
of pharmaceutical companies which invest in vaccines
for diseases of poverty, as well as the fraction of their
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budgets which they are prepared to commit to this
end.
Registration Issues
Regulatory Authority Capacity Issues
Generally, the regulatory authorities which are the
best resourced—and consequently the most capable—
of efficiently conducting competent and rigorous
reviews of clinical development plans, clinical trial
protocols and applications for licensure, are located in
countries or regions of the world which do not have a
high burden of TB. Examples are the FDA in the
United States, the European EMEA, and the regulatory
authorities of Japan and Australia. The converse is
unfortunately also largely true: many high TB burden
countries have poorly resourced, inexperienced regula-
tory authorities which do not have such capacity. In the
worst case, a high burden country may have no
regulatory authority and very little ethical review
capacity. This potentially creates an opening for
unethical, insufficiently regulated trials to be conducted
by unscrupulous researchers. In the middle ground are
high burden countries with some resources and some
structures which can render a competent review; but,
because of their resource constraints, review in such
countries can take a disproportionately long time.
Limited capacity and resources results in delays, not
only for protocol approval but also for registration of
new, effective products. In high burden countries, this is
far from an ideal situation.
The WHO has established a task force with the
specific aim of improving regulatory capacity in
developing countries (Brennan et al. 2007). Experi-
enced regulators from both the FDA and EMEA are
working together with developing world regulators in
order to build capacity, exchange experiences and
provide support. Ideally, a new TB vaccine will
undergo parallel registration with either the EMEA
or the FDA, and simultaneously within the develop-
ing world, for example, with the South African
Medicines Control Council (MCC).
One further regulatory issue relates to how wide
such registration can and should be. If the efficacy of
a new TB vaccine is satisfactorily demonstrated in
one population in one country (e.g. in South African
infants), could the vaccine, on the basis of the same
results, also be registered for use in other age groups
within the same country and/or for use in the same
age group in other countries? Careful regulatory
advice regarding bridging studies will be required.
Deployment
Post Registration Issues
When a TB vaccine is granted registration we will
have an ethical obligation to ensure that it is made
available to those most at risk. Given that approxi-
mately one third of the world’s population is infected
with TB and that tens of millions of infants born
every year are at risk of acquiring infection, supplying
enough vaccine will be a challenge and raises issues
of international distributive justice.
Many public funding agencies and universities
incorporate humanitarian access rights into their
stated missions, statutes or charters. For example,
the stated mission of the Aeras Global TB Vaccine
Foundation (www.aeras.org) is to develop effective
TB vaccine regimens that will prevent TB in all age
groups and will be affordable, available and adopted
worldwide. To ensure future access, Aeras
obtains rights and/or licenses to distribute vac-
cines in resource-poor countries … partners with
vaccine developers that agree to adequate supply
and affordable production and distribution costs
… shares financial risk to spur investment by
outside vaccine developers … [and] develops
manufacturing capacity to accelerate production
and distribution at the lowest possible cost.
Many other charities and funding organizations
have similar aims. The mission of The Wellcome
Trust (www.welcome.ac.uk) is “to foster and promote
research with the aim of improving human and animal
health”. The European & Developing Countries
Clinical Trials Partnership (EDCTP, www.edctp.org)
was created in 2003 as a European response to the
global health crisis caused by the three main poverty-
related diseases of HIV/AIDS, malaria and tubercu-
losis. The mission of EDCTP is to accelerate the
development of new or improved drugs, vaccines and
microbicides against HIV/AIDS, malaria and tuber-
culosis, with a focus on phase II and III clinical trials
in sub-Saharan Africa. To achieve this, EDCTP
supports multicentre projects which combine clinical
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trials, capacity building and networking. The aim of
integrating these three activities is to ensure that the
developed capacity is utilised to successfully conduct
the clinical trials in a sustainable way. All EDCTP-
funded projects are undertaken in partnership with
sub-Saharan African countries, to ensure synergy and
optimal use of resources and to create a win-win
situation for all parties involved.
Use of an Un-registered Vaccine
Should We be Using these Vaccines as
Immunotherapeutics in Drug Resistant TB?
At the World Lung Health meeting in Paris in
October 2008, early results of the “DarDar trial”, a
Phase III efficacy trial of a novel TB vaccine, M.
vaccae, in HIV infected adults in Tanzania, were
presented (Alcorn 2008). The trial showed a signif-
icant reduction (37%) in the rate of culture positive
TB disease in those who received the vaccine
compared to those who received placebo. These
results show that a TB vaccine can not only prevent
disease but may be useful in the treatment of existing
TB disease.
The last few years have seen the identification of
extensively drug resistant strains of M. tb (XDR TB)
and a greater understanding of the extent of multi
drug resistant (MDR) strains of M. tb throughout the
world (CDC 2006; Gandhi et al. 2006). Treatment of
MDRTB and particularly XDR TB is much more
expensive, more toxic and less successful than
treatment of drug sensitive strains of M. tb
Once we have an indication that a particular new
TB vaccine may be effective in preventing TB
disease, should such vaccines be made available,
prior to full registration and licensure for therapeutic
use in patients suffering from XDR or MDR TB?
The FDA does have a mechanism for distribution
of a medicinal product after efficacy has been
demonstrated but before marketing has been autho-
rized called “Treatment Investigational New Drugs”
or “Treatment IND” (entered into the Federal Regis-
ter, May 22, 1987). However, very few applications
have been granted and safety and efficacy data on test
subjects must still be collected.
It is important to consider the impact this could
have on the registration process if there were an
adverse event (AE). The risk of an AE if a new
vaccine were to be administered to a patient with TB
disease, particularly a drug-resistant strain of M. tb, is
potentially high. It may be difficult to ascertain the
causality of such an AE, and either (a) the AE may be
reported as being related to vaccination, which may
delay or even prevent registration of the vaccine for
prophylactic use or (b) the AE may be reported as not
being related to vaccination, but the timing may mean
it is impossible to prove this conclusively. Develop-
ment of a vaccine which may have been of enormous
use as a prophylactic vaccine in one population could
therefore be stopped because of the occurrence of an
AE in very high risk group.
Further Challenges Which may Arise if a Vaccine
Works
What follows are some "thought experiments" using a
number of different scenarios and illustrating some of
the ethical issues relating to vaccine deployment,
particularly in the early stages after licensing.
Justice and the Distribution of a TB Vaccine
It is unlikely that any new vaccine will be immedi-
ately available in sufficient quantity to meet the
urgent and enormous global need. In addition to
vaccine availability, logistical requirements such as a
public health infrastructure for vaccine deployment
and cold chain storage will need to be met. This will
be the case particularly if an effective vaccine is to be
administered to adolescents and young adults. At
present there are no routine vaccination programmes
outside of infancy in most developing countries, yet
adolescents and young adults form an important target
population for a new TB vaccine. It is possible,
therefore, that some form of prioritization will have to
be instituted, at least with regard to the initial rollout
of the new vaccine.
Factors which would need to be considered when
prioritizing countries (or groups within countries)
include the incidence (and incidence rate) of TB
infection and disease; the prevalence (and prevalence
rates) of HIV infection and AIDS; the ability of an
immunization program to effectively deliver the new
vaccine (including the ability to maintain the cold
chain if required, reach all communities, maintain
records and conduct post-licensing surveillance for
adverse events following immunization); the presence
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of competing priorities on their health agenda (for
example a health ministry may not wish to divert
scarce resources from a campaign which aims to get
insecticide treated bed-nets to families with young
children if that is the national priority at the time); the
presence or absence of political support at various
levels for such a campaign (e.g. the regional offices of
UNICEF and the WHO, the national health depart-
ment); and the availability of other means of prevent-
ing progression from TB infection to TB disease (e.g.
chemoprophylaxis). Some might argue that it would
be illogical and even unethical to deploy a new
vaccine unless a reasonably well-functioning TB
control program is already in place; a surveillance
programme, for example, would be necessary to
demonstrate an effect of the vaccine on rates of TB
infection and disease. However, countries or cities
without such programmes will be among the places
most in need of a new, effective vaccine, as decades
of ineffective and suboptimal case detection and
treatment programs have had little or no effect on
the burden of disease there.
If efficacy trials of a vaccine demonstrate higher
efficacy in some subgroups than others (e.g. one gender,
a particular age group, or those with HIV infection),
then it might be logical to target these groups first, if
vaccine supplies are limited and if this approach is
practical. Another approach would be to target the most
vulnerable (e.g. those living in extreme poverty,
children and the elderly) on the basis that they are less
able to effectively compete for humanitarian aid and are
most likely to benefit from vaccination.
Duty to Treat TB Patients and Vaccination
of Healthcare Workers
We use the term “healthcare workers” here in the
broadest sense and intend it to include physicians,
nurses, radiographers, physiotherapists, social work-
ers, Directly Observed Treatment, Short-course
(DOTS) supporters and supervisors, support staff
such as hospital cleaners: everyone with whom TB
patients may come into significant contact. Healthcare
workers are a special case for a number of reasons.
Firstly they are at higher risk of exposure and
consequently infection, because of their work. Sec-
ondly, their continued health and well being and
ability to work is necessary for the welfare of those
already suffering from TB and requiring or receiving
TB treatment. Thirdly, should they develop TB, they
may well present a risk of infection to other patients
and colleagues. Lastly, healthcare workers in some
settings have been shown to have a higher prevalence
of HIV infection (Connelly et al. 2007; Shisana et al.
2004), placing them more at risk of developing TB
should they become infected with the bacillus.
In view of the above, it may be appropriate to
consider healthcare workers as a priority group when
allocation decisions regarding a new TB vaccine are
made. In a developing country setting, where the
prevalence of TB disease is high, this would most
realistically be achieved by vaccinating all healthcare
workers.
Third-party Notification
Close contacts of TB patients, particularly of patients
with smear positive disease, are at increased risk of
infection and 50% of those who progress on to
develop disease do so within the first 1–2 years
(Morrison et al. 2008). An effective new vaccine may
well reduce either the establishment of infection in
those exposed, or the development of disease in
those infected. Prophylactic vaccination of such
contacts may therefore be an effective public health
measure.
It is likely that any new TB vaccine would be as
effective against drug resistant strains of M. tb as it
would against drug sensitive strains. In addition, drug
resistant strains of M. tb are not currently considered
intrinsically any more infectious than fully sensitive
M. tbs isolates, although patients may remain sputum
smear and/or culture positive for longer (National
Institute for Health and Clinical Excellence 2006).
Contacts of MDR/XDR TB patients should therefore
be at least as entitled to prophylactic vaccination as
contacts of drug sensitive TB patients. However, the
fact that therapeutic options for the treatment of drug
resistant strains of M. tb are more limited, less
effective, more prolonged, more toxic, more expen-
sive and less readily available in many high burden
countries may mean that public health is best served
by such contacts being given priority over contacts of
patients with drug sensitive strains of M. tb. MDR/
XDR TB patients may voluntarily inform their close
contacts of their exposure to the disease; but they
sometimes choose not to do so. In the latter case an
ethical dilemma arises, because a breach of patient
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confidentiality may be necessary to protect the
exposed individual’s right to life.
Mandatory Treatment
If there was an outbreak of XDR-TB, as for example
in the Tugela Ferry outbreak (Gandhi et al. 2006), and
an effective vaccine existed, a reasonable public
health measure might be to “ring vaccinate” everyone
in the immediate geographical area. The effectiveness
of such a strategy would depend on the level of herd
immunity achieved. Thus it might be necessary for a
national authority to insist on vaccination, and to
thereby override the rights of individuals. Such a
measure may be seen as the most efficient and cost
effective way to control such an outbreak.
Factors to be considered before such a decision could
be made would include the magnitude of the risk (the
closeness and duration of the contact, the risk of
infection given contact, estimates as to the transmissi-
bility of the strain, the risk and likely timing of disease
given infection, the prognosis and treatment options and
effectiveness should disease develop and the risk of
adverse reactions to the vaccination) and the likely
magnitude of the benefit (the demonstrated vaccine
efficacy against ordinary and MDR/XDR TB).
Conclusions
There are many complex ethical issues which arise at
all stages of TB vaccine development. Many of these
are common to those previously described in the
context of TB disease and further ethical discussion
about how to strike a balance between rights/liberties
of infected individuals and the greater good of society
would be useful for considering the ethical issues
arising from TB vaccine development. Vaccination
has enabled the eradication of smallpox and virtual
eradication of polio from the world. Development of a
TB vaccine could be considered a moral obligation as
reducing the morbidity and mortality of TB disease
through the development and deployment of an
effective vaccine would reduce the occurrence of
conflict between the rights and liberties of the infected
individual versus those of society.
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